Physician profile
Joseph Levy
NPI 1497850937
$2,201.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $984 · 2021: $393.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,027.57 | 2019-2020 | |
| Boston Scientific Corporation | $337.68 | 2019-2021 | |
| Astellas Pharma US INC | $285.25 | 2019-2021 | |
| Teleflex LLC | $208.07 | 2021 | |
| Allergan, INC. | $125.00 | 2020 | |
| Karl Storz Endoscopy-America | $62.50 | 2019 | |
| Janssen Biotech, INC. | $31.93 | 2019 | |
| Amgen INC. | $25.23 | 2019 | |
| 180 Medical, INC. | $23.57 | 2019 | |
| Laborie Medical Technologies Corp. | $23.10 | 2020 | |
| Travere Therapeutics, INC. | $19.35 | 2019 | |
| Blue Earth Diagnostics | $17.10 | 2019 | |
| Merck Sharp & Dohme LLC | $15.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.